RAPID-I, NCT03684278: Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial |
|
|
| Recruiting | 2 | 290 | Europe | Infusion of 5 mg/kg Infliximab, Remicade, Infusion of 10 mg/kg Infliximab, 0.9% Sodium Chloride (Placebo) | University of Liverpool, Bangor University, Liverpool University Hospitals NHS Foundation Trust, Medical Research Council, National Institute for Health Research, United Kingdom, Merck Sharp & Dohme LLC | Acute Pancreatitis | 07/26 | 03/27 | | |
NCT03795701: To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity |
|
|
| Completed | N/A | 73 | US | Saxenda®, Liraglutide 3.0, Placebo | Texas Tech University, Novo Nordisk A/S | Obesity | 05/22 | 05/22 | | |
